- Home
- HSCS vs REVB Comparison
HSCS vs REVB Comparison
Compare HSCS & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- REVB
- Stock Information
- Founded
- HSCS 2007
- REVB 2020
- Country
- HSCS United States
- REVB United States
- Employees
- HSCS N/A
- REVB N/A
- Industry
- HSCS Medical Specialities
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- REVB Health Care
- Exchange
- HSCS Nasdaq
- REVB Nasdaq
- Market Cap
- HSCS 3.7M
- REVB 3.8M
- IPO Year
- HSCS 2022
- REVB N/A
- Fundamental
- Price
- HSCS $3.94
- REVB $2.88
- Analyst Decision
- HSCS Strong Buy
- REVB
- Analyst Count
- HSCS 2
- REVB 0
- Target Price
- HSCS $13.00
- REVB N/A
- AVG Volume (30 Days)
- HSCS 187.6K
- REVB 269.2K
- Earning Date
- HSCS 07-24-2025
- REVB 08-08-2025
- Dividend Yield
- HSCS N/A
- REVB N/A
- EPS Growth
- HSCS N/A
- REVB N/A
- EPS
- HSCS N/A
- REVB N/A
- Revenue
- HSCS $4,350.00
- REVB N/A
- Revenue This Year
- HSCS $21,003.45
- REVB N/A
- Revenue Next Year
- HSCS $533.33
- REVB N/A
- P/E Ratio
- HSCS N/A
- REVB N/A
- Revenue Growth
- HSCS N/A
- REVB N/A
- 52 Week Low
- HSCS $2.36
- REVB $2.11
- 52 Week High
- HSCS $6.47
- REVB $168.00
- Technical
- Relative Strength Index (RSI)
- HSCS 49.70
- REVB 44.79
- Support Level
- HSCS $3.62
- REVB $2.97
- Resistance Level
- HSCS $4.14
- REVB $3.18
- Average True Range (ATR)
- HSCS 0.67
- REVB 0.23
- MACD
- HSCS -0.05
- REVB 0.13
- Stochastic Oscillator
- HSCS 12.15
- REVB 60.37
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).